HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3981-3983

  Gonzalez Serna, Alejandro ^a   Romero Sánchez, María Concepción ^a   Ferrando Martinez, Sara ^b   Genebat, Miguel ^a   Vidal, Francesc ^c   Muñoz Fernández, Maria Ángeles ^b   Abad, María Antonia ^a   Leal, Manuel ^a   Ruiz Mateos, Ezequiel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; EVOLUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIROGENESIS; VIRUS LOAD;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYCLOHEXANES; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRIAZOLES; VIRAL LOAD;

EID: 84862519492     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00507-12     Document Type: Article

References (10)

1. Genebat M, et al. 2011. Maraviroc clinical test (MCT) effectiveness for CCR5 prescription in clinical practice, abstr PE7.9/8. 13th Eur. AIDS Conf./EACS, Belgrade, Serbia.
2. Genebat M, et al. 2010. Long-term immunovirological effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr. HIV Res. 8:482-486.
3. Genebat M, et al. 2009. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 64:845-849.
4. Gonzalez-Serna A, et al. 2010. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J. Clin. Microbiol. 48:4453-4458.
5. Koot M, et al. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4R cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
6. Lin NH, Kuritzkes DR. 2009. Tropism testing in the clinical management of HIV-1 infection. Curr. Opin. HIV AIDS 4:481-487.
7. Raymond S, et al. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16.
8. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. 2009. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94-102.
9. Toma J, Whitcomb JM, Petropoulos CJ, Huang W. 2010. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 24:2181-2186.
10. Westby M, et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.